Secrets of Human Milk Oligosaccharides: New Research Reveals Their Impact on Infant Health

New research sheds light on the power of human milk oligosaccharides (HMOs), revealing exciting links to infant gut health, immunity, brain development, and more. This article dives deep into a groundbreaking scientific paper, “Functional effects of human milk oligosaccharides (HMOs)” by Dinleyici et al., published in Gut Microbes, to bring you the latest information on these fascinating components of breast milk.

As mothers, we know that breast milk is the gold standard for infant nutrition. But did you know that a key part of its magic lies in a complex group of sugars called HMOs? These indigestible carbohydrates, found in much higher quantities in human milk than in any other animal milk, are the third most prevalent solid component after lactose and lipids.

While HMOs provide minimal nutritional value directly, they act as powerful prebiotics, nurturing the growth of beneficial bacteria in your baby’s gut, particularly Bifidobacterium species. This bifidobacteria-rich environment plays a crucial role in safeguarding your baby’s health by protecting against infections, strengthening the gut barrier, and producing beneficial metabolites.

What Makes HMOs So Unique?

HMOs are made up of five simple sugar building blocks: glucose, galactose, fucose, N-acetylglucosamine, and N-acetylneuraminic acid (a derivative of sialic acid). These building blocks can be arranged in over 200 different ways, creating a diverse and complex pool of HMOs.

The specific types and amounts of HMOs present in breast milk vary greatly from mother to mother. This variation is influenced by a number of fascinating factors, including:

Secretor Status: Determined by the FUT2 gene, secretor status dictates whether a mother produces specific enzymes that add fucose to HMOs. Secretor mothers (70-80% of women) have higher overall HMO concentrations and a greater abundance of certain fucosylated HMOs like 2’-fucosyllactose (2’-FL) and lacto-N-fucopentaose I (LNFP I).
Lewis Blood Type: The FUT3 gene, responsible for the Lewis blood group, influences another enzyme that adds fucose to HMOs. Lewis-positive mothers produce 3-fucosyllactose (3’-FL) and lacto-N-fucopentaose II (LNFP II), while Lewis-negative mothers do not.
Geographic Location: Researchers have observed significant variations in HMO profiles across different geographic regions. For example, 3’-FL concentrations were found to be four times higher in milk samples from Sweden compared to those from rural Gambia.
Season: Even the time of year can affect HMO composition! A study in Gambia found that mothers produced lower levels of certain HMOs, like lacto-N-neotetraose (LNnT), during the wet season compared to the dry season.
Maternal Diet and Weight: While the influence of diet and weight on HMOs is still being investigated, some studies suggest that pre-pregnancy BMI and dietary factors, particularly in secretor mothers, may play a role in shaping HMO profiles.
Stage of Lactation: HMO concentrations tend to be highest in colostrum (the first milk produced after birth) and decrease over the course of lactation. However, some HMOs, like 3’-sialyllactose (3’-SL), 3’-FL, and disialyllacto-N-tetraose (DSLNT), actually increase in concentration throughout the first months of breastfeeding.

HMOs and Infant Growth:

While total HMO intake doesn’t seem to directly correlate with overall growth and adiposity, research has revealed that specific HMOs may play a role in regulating infant growth patterns during the first six months of life.

HMO-Microbiota Interaction: The complex interplay between specific HMOs and the infant’s developing gut microbiome may influence growth patterns. For instance, some HMOs appear to promote the growth of specific bacteria that regulate fat accumulation, potentially offering protection against later-life obesity.
Food Responsiveness and Appetite: HMOs may also impact how babies respond to food and regulate their appetite, possibly through microbiome-driven processes that affect the entero-endocrine system (a network of hormones in the gut) or the central nervous system.

HMOs: A Powerful Shield Against Infections:

One of the most compelling aspects of HMOs is their ability to protect infants from infections. Research suggests that HMOs may function as “decoy receptors,” mimicking the binding sites on cells that pathogens typically use to latch onto and cause infection. By binding to these pathogens, HMOs prevent them from attaching to the gut lining and being absorbed into the body.

Several studies have linked specific HMOs to protection against various infections:

Diarrhea: 2’-FL has been associated with a reduced risk of diarrhea caused by Campylobacter jejuni and the stable toxin of Escherichia coli. Lacto-N-difucohexaose I (LNDFH-I), another fucosylated HMO, appears to offer protection against calicivirus diarrhea, including norovirus.
Respiratory Infections: Higher levels of LNFP-II in colostrum have been linked to fewer respiratory problems in infants by 6 and 12 weeks of age. 2’-FL has also demonstrated antiviral activity against influenza in animal models.
Necrotizing Enterocolitis (NEC): This serious condition primarily affecting premature infants has been linked to lower HMO diversity in breast milk. Specifically, DSLNT has been associated with a lower risk of NEC, potentially due to its role in supporting a healthy gut microbiome development.
Sepsis: FDSLNH, a complex fucosylated HMO, has been found to protect against late-onset neonatal sepsis in very-low-birth-weight infants.

Building a Stronger Immune System:

HMOs not only offer direct protection against pathogens but also play a crucial role in shaping the development of your baby’s immune system.

Gut Microbiome Modulation: The bifidobacteria-rich gut environment fostered by HMOs produces short-chain fatty acids (SCFAs) like butyrate and propionate. These SCFAs act as anti-inflammatory agents, support the gut barrier, and influence immune cell activity.
Direct Immune Cell Interaction: Research suggests that HMOs can also directly interact with immune cells, influencing their development and activity. For example, 2’-FL has been shown to promote a Th1 immune response, important for fighting off infections, while 3’-SL can stimulate the production of cytokines that boost both Th1 and Th17 immune cells.
Allergy Prevention: The immunomodulatory effects of HMOs, combined with their influence on the gut microbiome, may also play a role in reducing the risk of developing allergies. Studies have shown that consumption of breast milk containing FUT2-dependent oligosaccharides (like 2’-FL) is associated with a lower incidence of IgE-mediated eczema in infants born via C-section.

Boosting Brain Development and Cognitive Function:

Emerging research is uncovering the exciting role of HMOs in supporting brain development and cognitive function.

Sialic Acid Power: Sialylated HMOs, like 3’-SL and 6’-SL, are rich in sialic acid, a crucial nutrient for brain development. Studies have linked higher 6’-SL levels to better cognitive and motor development at 18 months of age and better language development at 12 months.
Fucosylated HMOs and Learning: Fucosylated HMOs, like 2’-FL, may also be involved in brain development, as fucosylated proteins are found in high concentrations in areas of the brain involved in memory and learning.

HMOs and Infant Formula:

While breastfeeding remains the ideal way to provide infants with HMOs, researchers are actively exploring the potential of adding HMOs to infant formula. These human-identical milk oligosaccharides (HiMOs), produced through fermentation or other techniques, are not derived from human milk but have the same molecular structure as the HMOs found in breast milk.

Several clinical trials have investigated the safety and benefits of adding HiMOs to infant formula, yielding encouraging results:

Growth and Tolerance: Formulas supplemented with 2’-FL, LNnT, or a blend of five HMOs have been shown to be safe and well-tolerated, supporting normal growth patterns in infants.
Microbiota Modulation: HiMO supplementation can shift the gut microbiome of formula-fed infants closer to that of breastfed infants, increasing the abundance of beneficial bacteria like Bifidobacterium and reducing the levels of potentially harmful bacteria like Clostridium difficile.
Infection Prevention: Studies have reported a lower incidence of respiratory infections and bronchitis, as well as a reduced need for antibiotics and antipyretics, in infants fed HMO-supplemented formulas compared to those fed standard formulas.
Allergy Management: Adding HMOs, specifically 2’-FL and LNnT, to extensively hydrolyzed formulas (used for infants with cow’s milk protein allergy) has been shown to reduce allergy symptoms and improve gut health.

The Future of HMO Research:

HMO research is still a burgeoning field with much to uncover. While the initial findings are promising, further research is needed to fully understand the diverse roles of HMOs and their long-term impact on infant health.

The ideal dosage of HMOs in infant formula, the complex interplay between specific HMOs and the human milk microbiome, and the potential benefits of adding a wider variety of HiMOs to formula are all areas ripe for future investigation.

This exciting research on HMOs highlights the incredible complexity and power of breast milk. It also offers hope for formula-fed infants, as the addition of HMOs to formula holds the potential to bridge the gap between breast milk and formula, providing infants with some of the remarkable benefits of these extraordinary sugars.

Lisoderm